This inventor holds 2 USPTO granted patents. Top assignees: Biomeasure Incorporated, Societe De Conseils De Recherches Et D'applications Scientifiques Sas. Active years: 1998-2004.
Company Filing History:
1 out of 52 
1 out of 47 Years Active: 1998-2004
Title: Simon Jon Dunmore: Innovator in Amylin Release Inhibition
Introduction
Simon Jon Dunmore is a notable inventor based in Buckingham, GB. He has made significant contributions to the field of biochemistry, particularly in the area of amylin release inhibition. With a total of 2 patents, his work has implications for treating conditions related to hyperamylinemia.
Latest Patents
Dunmore's latest patents focus on the inhibition of amylin release. One of the methods he developed involves determining the ability of a compound to bind to the somatostatin type-5 receptor (SSTR-5) and inhibit amylin release. This method includes obtaining a preparation that contains SSTR-5, incubating it with a compound and a SSTR-5 ligand, and determining the compound's ability to compete for binding. If the compound binds to SSTR-5, pancreatic cells are obtained, and the compound is incubated with these cells and an amylin release stimulator. The ability of the compound to inhibit amylin release is then assessed. Additionally, he disclosed a method for treating hyperamylinemia using a ligand selective for SSTR-5.
Career Highlights
Throughout his career, Simon Jon Dunmore has worked with various companies, including Biomeasure Incorporated and Société de Conseils de Recherches et d'Applications Scientifiques SAS. His experience in these organizations has contributed to his expertise in the field of biochemistry and patent development.
Collaborations
Dunmore has collaborated with notable individuals in his field, including Michelle Davenport and Michael Anthony Cawthorne. These collaborations have likely enriched his research and innovation efforts.
Conclusion
Simon Jon Dunmore is a distinguished inventor whose work in amylin release inhibition has the potential to impact medical treatments for hyperamylinemia. His contributions to the field are significant and reflect his dedication to advancing biochemistry.